Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin
Authors:
- James F. HollandJHJames F. Holland
- James S. RyderJRJames S. Ryder
- Robert G. KonefalRKRobert G. Konefal
- George J. BekesiGBGeorge J. Bekesi
- Rosalie OdchimarRORosalie Odchimar
- Ronald GordonRGRonald Gordon
- 1 June 1989
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 16, 67-81
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.Journal of Clinical Oncology, 1989
- Pinocchio cells: morphologically atypical immunologically heterogeneous lymphocytes induced by treatment with interleukin 2Immunology Letters, 1988
- Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1JNCI: Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.Journal of Clinical Oncology, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Interleukin 2 enhances natural killer cell activity through induction of gamma interferonInfection and Immunity, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.Journal of Experimental Medicine, 1982
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.Journal of Experimental Medicine, 1982